OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...
OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...
FOX 26 Houston on MSN26d
What is Osteosarcoma?Turner was elected to serve Texas' 18th Congressional in November 2024. Turner was diagnosed with Osteosarcoma, a form of ...
OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2.
Biosciences, announced that its collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an ...
Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time Osteosarcoma (OS) is the most prevalent ...
Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical ...
About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.
The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback